Literature DB >> 7551381

Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial.

A M Schols1, P B Soeters, R Mostert, R J Pluymers, E F Wouters.   

Abstract

Nutritional depletion commonly occurs in patients with COPD, causing muscle wasting and impaired physiologic function. Two hundred seventeen patients with COPD participated in a placebo-controlled, randomized trial investigating the physiologic effects of nutritional intervention alone (N) for 8 wk or combined with the anabolic steroid nandrolone decanoate (N + A). Nandrolone decanoate or placebo (P) was injected intramuscularly (women, 25 mg; men, 50 mg) in a double-blind fashion on Days 1, 15, 29, and 43. Nutritional intervention consisted of a daily high caloric supplement (420 kcal; 200 ml). Also, all patients participated in an exercise program. In the depleted patients, both treatment regimens induced a similar significant body weight gain (2.6 kg) but different body compositional changes. Particularly in the last 4 wk of treatment, weight gain in the N group was predominantly due to an expansion of fat mass (p < 0.03 versus P and N + A), whereas the relative changes in fat-free mass (FFM) and other measures of muscle mass were more favorable in the N + A group (p < 0.03 versus P). Maximal inspiratory mouth pressure improved within both treatment groups in the first 4 wk of treatment, but after 8 wk only N + A was significantly different from P (p < 0.03). Nutritional supplementation in combination with a short course of anabolic steroids may enhance the gain in FFM and respiratory muscle function in depleted patients with COPD without causing adverse side effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551381     DOI: 10.1164/ajrccm.152.4.7551381

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  62 in total

Review 1.  Athletes and doping: effects of drugs on the respiratory system.

Authors:  P N Dekhuijzen; H A Machiels; L M Heunks; H F van der Heijden; R H van Balkom
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

Review 2.  Enhancing physical performance in chronic obstructive pulmonary disease.

Authors:  M C Steiner; M D Morgan
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

3.  Lung volume reduction surgery and nutritional status in patients with severe emphysema.

Authors:  K Nezu; T Kawaguchi; M Kimura; M Yasukawa; K Kushibe; S Taniguchi; M Yoshikawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-09

Review 4.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

5.  High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway.

Authors:  Ahmed Elsayem; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2007-07-17       Impact factor: 3.603

6.  Sarcopaenia in chronic obstructive pulmonary disease.

Authors:  Michael C Steiner
Journal:  Thorax       Date:  2007-02       Impact factor: 9.139

7.  Comparison of Effects of Endurance and Strength Training Programs in Patients with COPD.

Authors:  Michael J Berry; Katherine L Sheilds; Norman E Adair
Journal:  COPD       Date:  2018-04-16       Impact factor: 2.409

8.  Fat-free mass depletion in patients with COPD in Brazil: development of a new cutoff point and its relation with mortality and extrapulmonary manifestations.

Authors:  A Travassos; A Rodrigues; K C Furlanetto; L Donária; G W Bisca; A G Nellessen; F Pitta; N A Hernandes
Journal:  Eur J Clin Nutr       Date:  2017-07-19       Impact factor: 4.016

9.  Routine protein energy supplementation in adults: systematic review.

Authors:  J Potter; P Langhorne; M Roberts
Journal:  BMJ       Date:  1998-08-22

Review 10.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.